asset swap
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
This is the first treatment breakthrough in pulmonary fibrosis in over a decade
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim
The collaboration began in 2013 and was later expanded in 2020 and 2023
Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
SPMS is a debilitating stage of MS where patients experience increasing levels of disability
Sanofi appoints Paulo Fontoura as Global Head of R&D
Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche
Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector
It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma
Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases
The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes
Sanofi announces positive results for venglustat in type 3 Gaucher disease
There are currently no approved treatments for the neurological symptoms of this disease
Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease
Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed